Streetbeat News

Earnings

CROX

Crocs (NASDAQ:CROX) reported Q2 2024 adjusted EPS of $4.01, beating the estimate of $3.56. Sales were $1.112 billion, surpassing the $1.102 billion estimate and showing a 3.69% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:01 am

RACE

Ferrari reported its Q2 2024 adjusted EPS at €2.29, surpassing the estimated €2.07.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:01 am

BIIB

Biogen has updated its 2024 financial guidance, expecting adjusted EPS of $15.75-$16.25, an improvement from prior guidance. The company anticipates a low-single digit percentage decline in total revenue, with core pharmaceutical revenue remaining flat. Operating income is expected to grow at a mid- to high-teen percentage, driven by improved cost of sales and lower operating expenses.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:01 am

COP

ConocoPhillips (NYSE:COP) reported Q2 2024 adjusted earnings per share (EPS) of $1.98, surpassing the analyst consensus estimate of $1.96. This represents a 7.61% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:01 am

TRN

Trinity Industries (NYSE:TRN) reported strong Q2 2024 earnings, with adjusted EPS of $0.66 beating the $0.34 estimate and sales of $841.4M surpassing the $769.4M estimate. This represents significant year-over-year growth in both earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:00 am

AME

AMETEK has revised its FY24 sales growth forecast to 5%-7%, down from the previous expectation of low double digits. The company also lowered its adjusted EPS forecast to $6.70-$6.80, compared to the prior range of $6.74-$6.86, with an estimate of $6.84.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:00 am

BIIB

Biogen shares are trading higher following better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:59 am

KTB

Kontoor Brands (NYSE:KTB) reported Q2 earnings of $0.98 per share, beating the analyst estimate of $0.88. Sales were $606.90 million, also surpassing the estimate of $595.62 million. Despite the beats, sales decreased by 1.48% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:59 am

LH

Laboratory Corp (NYSE:LH) reported Q2 2024 adjusted EPS of $3.94, beating the $3.78 estimate and showing a 15.2% increase from last year. Sales were $3.220 billion, surpassing the $3.185 billion estimate and marking a 6.13% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:59 am

BIIB

Biogen reported its Q2 2024 results, with adjusted EPS of $5.28 beating the estimate of $4.03, and sales of $2.465 billion surpassing the expected $2.382 billion.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:58 am